title: Can intensity of long-term follow-up for survivors of childhood and teenage cancer be determined by therapy-based risk stratification?
abstract: OBJECTIVE
  To determine the feasibility of therapy-based, risk-stratified follow-up guidelines for childhood and teenage cancer survivors by evaluating adverse health outcomes in a survivor cohort retrospectively assigned a risk category.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Tertiary level, single centre, paediatric cancer unit in South East Scotland.
  
  
  METHODS
  All children and teenagers diagnosed with cancer (<19 years) between 1 January 1971 and 31 July 2004, who were alive more than 5 years from diagnosis formed the study cohort. Each survivor was retrospectively assigned a level of follow-up, based on their predicted risk of developing treatment-related late effects (LEs; levels 1, 2 and 3 for low, medium and high risk, respectively). Adverse health outcomes were determined from review of medical records and postal questionnaires. LEs were graded using the Common Terminology Criteria for Adverse Event, V.3.
  
  
  RESULTS
  607 5-year survivors were identified. Risk stratification identified 86 (14.2%), 271 (44.6%) and 250 (41.2%) as levels 1, 2 and 3 survivors, respectively. The prevalence of LEs for level 1 survivors was 11.6% with only one patient with grade 3 or above toxicity. 35.8% of level 2 survivors had an LE, of whom 9.3%, 58.8%, 18.5%, 10.3% and 3% had grades 1, 2, 3, 4 and 5 toxicity, respectively. 65.2% of level 3 survivors had LE, of whom 5.5% (n=9), 34.4% (n=56), 36.2% (n=59), 22.1% (n=36) and 1.8% (n=3) had grades 1, 2, 3, 4 and 5 toxicity, respectively.
  
  
  CONCLUSIONS
  Therapy-based risk stratification of survivors can predict which patients are at significant risk of developing moderate-to-severe LEs and require high-intensity long-term follow-up. Our findings will need confirmation in a prospective cohort study that has the power to adjust for all potentially confounding variables.
authors.affiliation: Department of Oncology, Royal Hospital for Sick Children, Edinburgh, UK.
authors.forename: A B
authors.initials: AB
authors.lastname: Edgar
authors.forename: K
authors.initials: K
authors.lastname: Duffin
authors.forename: S
authors.initials: S
authors.lastname: Borthwick
authors.forename: P
authors.initials: P
authors.lastname: Marciniak-Stepak
authors.forename: W H
authors.initials: WH
authors.lastname: Wallace
references.citation: J Clin Oncol. 2009 May 10;27(14):2405-14
references.pmid: 19289611
references.citation: BMJ. 2008 Apr 5;336(7647):732-3
references.pmid: 18390499
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6071-3
references.pmid: 19901130
references.citation: J Cancer Surviv. 2012 Jun;6(2):163-71
references.pmid: 22124938
references.citation: Eur J Cancer. 2006 Dec;42(18):3186-90
references.pmid: 16989995
references.citation: J Clin Oncol. 2009 May 10;27(14):2339-55
references.pmid: 19364955
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3163-72
references.pmid: 11432882
references.citation: Eur J Cancer. 1998 Apr;34(5):694-8
references.pmid: 9713276
references.citation: Lancet Oncol. 2008 Mar;9(3):232-8
references.pmid: 18282804
references.citation: Pediatr Blood Cancer. 2004 Feb;42(2):161-8
references.pmid: 14752881
references.citation: Pediatr Clin North Am. 2002 Oct;49(5):1083-106, x
references.pmid: 12430627
references.citation: Cancer. 2000 Apr 1;88(7):1687-95
references.pmid: 10738228
references.citation: BMJ. 2001 Aug 4;323(7307):271-4
references.pmid: 11485960
references.citation: N Engl J Med. 2006 Oct 12;355(15):1572-82
references.pmid: 17035650
references.citation: Eur J Cancer. 2012 May;48(7):1066-73
references.pmid: 21737254
references.citation: Eur J Pediatr. 2000 Oct;159(10):750-8
references.pmid: 11039130
references.citation: Ann Oncol. 2007 Nov;18(11):1898-902
references.pmid: 17804470
references.citation: Eur J Cancer. 2002 Mar;38(4):468-77
references.pmid: 11872338
references.citation: J Clin Oncol. 2011 Nov 1;29(31):4181-8
references.pmid: 21947833
references.citation: Cancer. 2004 Feb 15;100(4):843-50
references.pmid: 14770443
references.citation: BMJ. 2013 Mar 27;346:f1190
references.pmid: 23535255
references.citation: Cancer J. 2005 Jul-Aug;11(4):340-54
references.pmid: 16197724
references.citation: Pediatr Blood Cancer. 2006 Feb;46(2):135-42
references.pmid: 16369921